How training and reduction of antispastic medication affects adults with severe cerebral palsy

Not Applicable

• Conditions: Gross motor function in cerebral palsy; Nervous System Diseases; Cerebral palsy

• Registration Number: ISRCTN66528622
• Lead Sponsor: niversity of Copenhagen

Brief Summary

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33523030/ (added 20/07/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-06-24
• Last Update Posted: 2 August 2021
• Study Completion: 2022-09-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

1. Diagnosed with cerebral palsy
2. GMFCS level between III-V
3. >18 years of age

Exclusion Criteria

Does not meet inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional ability measured by Gross Motor Function Measure (GMFM-88) at baseline; immediately following 4-week drug discontinuation and prior to starting the 12-week active intervention; immediately following the intervention; and at follow-up 1 month after finishing the intervention

Secondary Outcome Measures

Name	Time	Method
eurological screening including Modified Ashworth's Scale (MAS), Range of Motion (ROM), tendon reflex testing and 0-5 strength scale at baseline; immediately following 4-week drug discontinuation and prior to starting the 12-week active intervention; immediately following the intervention; and at follow-up 1 month after finishing the intervention